Ranibizumab side effects: what 26,388 FDA adverse event reports show
Drug class
Vascular Endothelial Growth Factor Inhibitor
Brand names
Susvimo
Who reports
26,388 reports · 85% serious · 5,093 with death outcome · 56% female
Used for
SUSVIMO (ranibizumab injection) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.1 ). Diabetic Macular Edema (DME) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.2 ).
What it is
Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor-A (VEGF-A).
Boxed warning
ENDOPHTHALMITIS The SUSVIMO implant has been associated with an up to 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab. Many of these events were associated with conjunctival retractions or erosions.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled — boxed warning The term (or its clinical synonym) appears in the FDA boxed warning: causality is regulator-recognised and considered serious.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 1,004 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Conjunctival retraction | 11 | 2,153.4 685.7–6,762.4ROR 2,154.3 · χ² 5,749 / p <1e-300 | 287.6 EB05 171.4 · IC025 +3.4 3/3 methods agree | Labeled — boxed warning exact term | serious n=8 | not reported in cached trials |
| Polypoidal choroidal vasculopathy | 199 | 1,442.8 1,141.9–1,823.1ROR 1,453.8 · χ² 100,363 / p <1e-300 | 484.4 EB05 430.5 · IC025 +7.6 3/3 methods agree | Not in label — unassessed | serious n=198 · ♀ 28% (drug 56%) · 97% clinician | not reported in cached trials |
| Foveal reflex abnormal | 11 | 1,435.6 531.0–3,881.6ROR 1,436.2 · χ² 5,070 / p <1e-300 | 269.8 EB05 160.7 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=11 | not reported in cached trials |
| Retinal pigment epithelial tear | 321 | 716.1 615.8–832.8ROR 724.9 · χ² 119,364 / p <1e-300 | 366.3 EB05 333.9 · IC025 +7.7 3/3 methods agree | Not in label — unassessed | serious n=321 | NCT00637377: 1/291 (0.3%) on Ranibizumab (serious AE) |
| Diabetic retinal oedema | 229 | 654.4 549.3–779.7ROR 660.2 · χ² 81,035 / p <1e-300 | 346.6 EB05 310.5 · IC025 +7.4 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=226 | not reported in cached trials |
| Conjunctival bleb | 24 | 648.0 377.4–1,112.9ROR 648.6 · χ² 8,133 / p <1e-300 | 276.8 EB05 195.8 · IC025 +4.7 3/3 methods agree | Labeled — boxed warning exact term | serious n=16 · 100% clinician | not reported in cached trials |
| Choroidal neovascularisation | 358 | 585.2 510.6–670.8ROR 593.3 · χ² 119,164 / p <1e-300 | 329.4 EB05 301.8 · IC025 +7.7 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=351 | NCT00637377: 1/291 (0.3%) on Ranibizumab (serious AE) |
| Subretinal fibrosis | 81 | 566.3 425.6–753.5ROR 568.1 · χ² 26,199 / p <1e-300 | 305.3 EB05 253.5 · IC025 +6.4 3/3 methods agree | Not in label — unassessed | serious n=77 | not reported in cached trials |
| Macular scar | 73 | 492.8 367.8–660.3ROR 494.1 · χ² 21,688 / p <1e-300 | 280.6 EB05 230.6 · IC025 +6.2 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=70 | NCT00637377: 1/309 (0.3%) on Ranibizumab (serious AE) |
| Detachment of retinal pigment epithelium | 311 | 443.6 386.2–509.5ROR 448.9 · χ² 87,391 / p <1e-300 | 278.7 EB05 253.6 · IC025 +7.4 3/3 methods agree | Labeled (related wording) related wording | serious n=311 · 92% clinician | NCT00637377: 38/291 (13.1%) on Ranibizumab |
| Retinal scar | 154 | 398.0 327.9–483.0ROR 400.3 · χ² 40,170 / p <1e-300 | 255.8 EB05 223.7 · IC025 +6.9 3/3 methods agree | Not in label — unassessed | serious n=153 | not reported in cached trials |
| Retinal cyst | 54 | 387.9 280.0–537.4ROR 388.7 · χ² 13,679 / p <1e-300 | 237.9 EB05 189.3 · IC025 +5.8 3/3 methods agree | Labeled (related wording) related wording | serious n=53 | NCT00637377: 13/291 (4.5%) on Ranibizumab |
| Subretinal fluid | 336 | 372.7 327.5–424.1ROR 377.5 · χ² 84,138 / p <1e-300 | 249.2 EB05 227.7 · IC025 +7.3 3/3 methods agree | Not in label — unassessed | serious n=327 · 92% clinician | not reported in cached trials |
| Age-related macular degeneration | 445 | 327.8 293.7–365.9ROR 333.4 · χ² 101,978 / p <1e-300 | 229.1 EB05 211.8 · IC025 +7.4 3/3 methods agree | Likely indication confounding term in indications | serious n=441 | NCT00637377: 3/309 (1.0%) on Ranibizumab (serious AE) |
| Conjunctival erosion | 31 | 292.5 193.6–441.7ROR 292.8 · χ² 6,345 / p <1e-300 | 188.6 EB05 139.2 · IC025 +5.0 3/3 methods agree | Labeled — boxed warning exact term | serious n=24 · 90% clinician | not reported in cached trials |
| Subretinal haematoma | 12 | 284.7 147.1–551.3ROR 284.9 · χ² 2,284 / p <1e-300 | 157.3 EB05 95.9 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=12 | not reported in cached trials |
| Retinal fibrosis | 18 | 276.4 161.5–472.9ROR 276.6 · χ² 3,449 / p <1e-300 | 168.3 EB05 112.6 · IC025 +4.2 3/3 methods agree | Labeled (related wording) related wording | serious n=18 | not reported in cached trials |
| Exudative retinopathy | 14 | 274.1 149.1–503.7ROR 274.2 · χ² 2,623 / p <1e-300 | 159.5 EB05 101.0 · IC025 +3.8 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=14 | not reported in cached trials |
| Detachment of macular retinal pigment epithelium | 13 | 261.0 139.4–488.9ROR 261.1 · χ² 2,334 / p <1e-300 | 152.6 EB05 94.9 · IC025 +3.6 3/3 methods agree | Labeled (related wording) related wording | serious n=13 | not reported in cached trials |
| Cataract traumatic | 10 | 244.7 120.3–497.7ROR 244.8 · χ² 1,668 / p <1e-300 | 138.1 EB05 80.2 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=10 | not reported in cached trials |
| Retinal neovascularisation | 58 | 240.3 179.1–322.4ROR 240.8 · χ² 10,394 / p <1e-300 | 173.7 EB05 139.3 · IC025 +5.7 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=58 | not reported in cached trials |
| Macular cyst | 17 | 208.0 121.9–355.0ROR 208.1 · χ² 2,606 / p <1e-300 | 139.2 EB05 92.0 · IC025 +4.0 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=17 | NCT00637377: 1/307 (0.3%) on Ranibizumab (serious AE) |
| Retinal oedema | 371 | 195.1 174.2–218.5ROR 197.9 · χ² 57,203 / p <1e-300 | 155.2 EB05 142.3 · IC025 +6.8 3/3 methods agree | Labeled (related wording) related wording | serious n=362 | NCT00637377: 34/291 (11.7%) on Ranibizumab |
| Retinopathy of prematurity | 107 | 192.2 155.6–237.3ROR 192.9 · χ² 16,186 / p <1e-300 | 150.4 EB05 128.0 · IC025 +6.2 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=107 · 100% clinician | not reported in cached trials |
| Retinal depigmentation | 58 | 186.1 139.8–247.8ROR 186.5 · χ² 8,480 / p <1e-300 | 143.5 EB05 115.1 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | serious n=57 · 93% clinician | not reported in cached trials |
| Pseudoendophthalmitis | 19 | 186.0 112.8–306.6ROR 186.1 · χ² 2,677 / p <1e-300 | 131.0 EB05 88.6 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=19 | NCT00509795: 1/304 (0.3%) on Ranibizumab (serious AE) |
| Macular ischaemia | 27 | 176.2 116.1–267.4ROR 176.4 · χ² 3,698 / p <1e-300 | 130.9 EB05 94.5 · IC025 +4.7 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=27 · 100% clinician | not reported in cached trials |
| Retinal aneurysm | 35 | 168.1 116.7–242.2ROR 168.4 · χ² 4,650 / p <1e-300 | 129.0 EB05 97.0 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious n=35 · 100% clinician | not reported in cached trials |
| Vitreous haemorrhage | 454 | 155.7 140.8–172.0ROR 158.4 · χ² 58,072 / p <1e-300 | 129.3 EB05 119.6 · IC025 +6.7 3/3 methods agree | Labeled — boxed warning exact term | serious n=438 | NCT00637377: 1/291 (0.3%) on Ranibizumab (serious AE) |
| Cataract nuclear | 104 | 149.4 121.2–184.2ROR 150.0 · χ² 12,752 / p <1e-300 | 122.9 EB05 104.3 · IC025 +6.0 3/3 methods agree | Labeled (related wording) related wording | serious n=102 | NCT00637377: 1/309 (0.3%) on Ranibizumab (serious AE) |
| Retinal exudates | 146 | 146.9 123.2–175.3ROR 147.8 · χ² 17,697 / p <1e-300 | 121.9 EB05 106.2 · IC025 +6.2 3/3 methods agree | Not in label — unassessed | serious n=145 | not reported in cached trials |
| Retinal drusen | 25 | 146.1 95.3–223.9ROR 146.2 · χ² 2,915 / p <1e-300 | 112.9 EB05 80.4 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=25 | not reported in cached trials |
| Macular pigmentation | 13 | 143.4 79.4–258.9ROR 143.4 · χ² 1,435 / p <1e-300 | 103.4 EB05 64.3 · IC025 +3.5 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=12 | not reported in cached trials |
| Vitreous adhesions | 17 | 138.7 82.8–232.2ROR 138.8 · χ² 1,859 / p <1e-300 | 104.4 EB05 69.1 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=17 | not reported in cached trials |
| Neovascular age-related macular degeneration | 197 | 132.0 113.5–153.4ROR 132.9 · χ² 21,801 / p <1e-300 | 111.9 EB05 99.4 · IC025 +6.2 3/3 methods agree | Likely indication confounding term in indications | serious n=191 | not reported in cached trials |
| Choroidal haemorrhage | 25 | 117.2 77.0–178.4ROR 117.3 · χ² 2,406 / p <1e-300 | 94.9 EB05 67.6 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=25 | NCT00509795: 1/304 (0.3%) on Ranibizumab (serious AE) |
| Macular fibrosis | 86 | 114.3 91.2–143.3ROR 114.7 · χ² 8,332 / p <1e-300 | 97.8 EB05 81.6 · IC025 +5.6 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=85 | not reported in cached trials |
| Ophthalmological examination abnormal | 22 | 114.1 73.0–178.4ROR 114.2 · χ² 2,055 / p <1e-300 | 92.0 EB05 64.0 · IC025 +4.3 3/3 methods agree | Reporting / coding artifact | serious n=20 | not reported in cached trials |
| Posterior capsule rupture | 10 | 113.5 58.5–220.3ROR 113.5 · χ² 878 / p 3e-193 | 83.9 EB05 48.7 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=10 | not reported in cached trials |
| Pseudophakia | 10 | 111.9 57.7–217.0ROR 111.9 · χ² 867 / p 8e-191 | 83.0 EB05 48.2 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=10 | not reported in cached trials |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Ranibizumab as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (12 of 40 signal terms matched).
- NCT00637377 — Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Ma (N=1240, PHASE3; 319 AE terms posted; arms: Ranibizumab 0.5mg Q4; Aflibercept Injection (EYLEA, VEGF Trap-; Aflibercept Injection (EYLEA, VEGF Trap-; Aflibercept Injection (EYLEA, VEGF Trap-)
- NCT00509795 — Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macul (N=1217, PHASE3; 348 AE terms posted; arms: Ranibizumab 0.5mg Q4; IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4; IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4; IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Death | 3,800 | 3.5 3.4–3.6ROR 3.9 · χ² 7,103 / p <1e-300 | 3.5 EB05 3.4 · IC025 +1.8 3/3 methods agree | Outcome field, not a reaction | serious PRR 2.4 | NCT00637377: 1/297 (0.3%) on Ranibizumab (serious AE) |
| Visual acuity reduced | 2,906 | 75.5 72.8–78.3ROR 84.7 · χ² 195,055 / p <1e-300 | 68.9 EB05 66.8 · IC025 +6.0 3/3 methods agree | Not in label — unassessed | serious PRR 60.4 | NCT00637377: 3/291 (1.0%) on Ranibizumab (serious AE) |
| Off label use (used outside approved label) | 1,722 | 1.6 1.5–1.7ROR 1.6 · χ² 379 / p 1e-84 | 1.6 EB05 1.5 · IC025 +0.6 | Reporting / coding artifact | serious PRR 1.1 | not reported in cached trials |
| Visual impairment | 1,647 | 10.8 10.3–11.3ROR 11.4 · χ² 14,473 / p <1e-300 | 10.6 EB05 10.2 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious PRR 9.6 | not reported in cached trials |
| Cerebrovascular accident (stroke) | 1,238 | 5.8 5.5–6.1ROR 6.1 · χ² 4,941 / p <1e-300 | 5.8 EB05 5.5 · IC025 +2.4 3/3 methods agree | Not in label — unassessed | serious PRR 3.9 | NCT00637377: 2/291 (0.7%) on Ranibizumab (serious AE) |
| Drug ineffective (drug did not work) | 1,209 | 0.7 0.7–0.8ROR 0.7 · χ² 129 / p 3e-30 | 0.7 EB05 0.7 · IC025 -0.5 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | serious PRR 1.0 | not reported in cached trials |
| No adverse event | 1,053 | 4.7 4.5–5.0ROR 4.9 · χ² 3,111 / p <1e-300 | 4.7 EB05 4.5 · IC025 +2.1 3/3 methods agree | Reporting / coding artifact | serious PRR 4.8 | not reported in cached trials |
| Blindness | 1,046 | 20.9 19.7–22.2ROR 21.8 · χ² 19,353 / p <1e-300 | 20.4 EB05 19.4 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious PRR 14.0 | NCT00637377: 1/307 (0.3%) on Ranibizumab (serious AE) |
| Eye haemorrhage | 1,044 | 67.3 63.2–71.6ROR 70.0 · χ² 62,747 / p <1e-300 | 62.0 EB05 58.9 · IC025 +5.8 3/3 methods agree | Labeled (related wording) related wording | serious PRR 43.4 | NCT00637377: 4/291 (1.4%) on Ranibizumab (serious AE) |
| Vision blurred (blurred vision) | 1,032 | 6.0 5.7–6.4ROR 6.2 · χ² 4,331 / p <1e-300 | 6.0 EB05 5.7 · IC025 +2.5 3/3 methods agree | Labeled — boxed warning synonym match | serious PRR 6.1 | NCT00509795: 12/304 (3.9%) on Ranibizumab |
| Eye pain | 961 | 14.1 13.2–15.0ROR 14.5 · χ² 11,465 / p <1e-300 | 13.8 EB05 13.1 · IC025 +3.7 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 16.0 | NCT00637377: 1/309 (0.3%) on Ranibizumab (serious AE) |
| Retinal haemorrhage | 797 | 100.3 93.3–107.9ROR 103.4 · χ² 69,415 / p <1e-300 | 88.9 EB05 83.8 · IC025 +6.3 3/3 methods agree | Labeled (related wording) related wording | serious PRR 60.8 | NCT00637377: 4/291 (1.4%) on Ranibizumab (serious AE) |
| Endophthalmitis | 734 | 110.9 102.7–119.6ROR 114.0 · χ² 69,918 / p <1e-300 | 97.0 EB05 91.2 · IC025 +6.4 3/3 methods agree | Labeled — boxed warning exact term | serious n=704 · 92% clinician | NCT00637377: 1/309 (0.3%) on Ranibizumab (serious AE) |
| Myocardial infarction (heart attack) | 690 | 3.1 2.9–3.4ROR 3.2 · χ² 1,000 / p 9e-220 | 3.1 EB05 2.9 · IC025 +1.5 3/3 methods agree | Not in label — unassessed | serious PRR 2.1 | NCT00637377: 1/291 (0.3%) on Ranibizumab (serious AE) |
| Cataract | 686 | 9.3 8.6–10.0ROR 9.5 · χ² 5,019 / p <1e-300 | 9.2 EB05 8.6 · IC025 +3.1 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 6.6 | NCT00637377: 5/291 (1.7%) on Ranibizumab (serious AE) |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Polypoidal choroidal vasculopathy — n=199, PRR 1,442.8
- Retinal pigment epithelial tear — n=321, PRR 716.1 (also seen in trial arm)
- Subretinal fibrosis — n=81, PRR 566.3
- Retinal scar — n=154, PRR 398.0
- Subretinal fluid — n=336, PRR 372.7
- Retinal depigmentation — n=58, PRR 186.1
- Retinal aneurysm — n=35, PRR 168.1
- Retinal exudates — n=146, PRR 146.9
- Retinal drusen — n=25, PRR 146.1
- Choroidal haemorrhage — n=25, PRR 117.2 (also seen in trial arm)
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Ranibizumab?
In FDA FAERS, the most frequently co-reported reaction terms for Ranibizumab are visual acuity reduced, visual impairment, cerebrovascular accident, blindness, eye haemorrhage, vision blurred. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Ranibizumab have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: ENDOPHTHALMITIS The SUSVIMO implant has been associated with an up to 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab. Many of these events were associated with conjunctival retractions or erosions.
Do FAERS signals prove that Ranibizumab causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 9c6d9e2a-9a77-4d11-b692-de87cfde3444, effective 20251121; matched on
openfda.generic_name.exact:"RANIBIZUMAB") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,044 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
RANIBIZUMAB, results-bearing studies sorted by enrollment)
Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.